Sartorius takes over the chromatography process equipment division from Novasep | Sartorius AG, January 6th, 2021


GOETTINGEN, Germany, March 23 / PRNewswire / – Planned transaction builds on the strategic partnership between the two companies in research and development

– Acquisition strengthens Sartorius position in downstream bioprocessing

The life science company Sartorius has signed an agreement through its subgroup Sartorius Stedim Biotech to take over the chromatography process systems from Novasep. The parties have agreed not to communicate the purchase price until the necessary regulatory approvals have been received. The division has expected sales of around 37 million euros in 2020 with double-digit profit margins and employs around 100 people, the majority of whom work at the Pompey site in northern France and some in the USA, China and India. The planned transaction is subject to antitrust approval (by the US Federal Trade Commission) and the information and consultation of the Novasep works council and is expected to be completed in the first half of 2021.

Novasep’s chromatography division comprises gel-based batch and intensive chromatography systems and focuses primarily on high pressure and reusable applications for smaller molecules such as oligonucleotides, peptides and insulin. Since 2018, Novasep and Sartorius have been working together on the development of an optimized system for membrane-based low-pressure chromatography, which processes larger molecules more productively and which is to be brought to market shortly.

“I am pleased that we will soon be intensifying our successful cooperation with the Novasep team under the Sartorius umbrella,” said Dr. René Fáber, member of the Sartorius Executive Board and head of the Bioprocess Solutions division. “The Novasep portfolio perfectly complements our existing chromatography offering and enables us to offer our customers more options for their manufacturing processes. Efficient downstream processes have been a challenge in our industry for years, and Sartorius is striving to accelerate this decisive step and simplify so that new drugs can be manufactured more efficiently. “

“This transaction is one of the first steps in our Rise-2 strategic program to focus the group on our core business,” said Dr. Michel Spagnol, President and CEO of Novasep. “We are excited to strengthen our relationship with the Sartorius team and believe that it is a great opportunity for the chromatography equipment business to realize its full potential and accelerate its growth under this new owner.”

This publication contains statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from these statements. Sartorius assumes no obligation to update such statements in light of new information or future events.

Sartorius in brief

The Sartorius Group is a leading international partner for biopharmaceutical research and industry. The Lab Products & Services division focuses on research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies and academic research institutions with innovative laboratory instruments and consumables. With a broad product portfolio with a focus on single-use solutions, the Bioprocess Solutions division helps ensure that biotech drugs and vaccines are manufactured safely and efficiently. The group is growing by an average of double digits per year and regularly supplements its portfolio with the acquisition of complementary technologies. In the 2019 financial year, the company achieved sales of around 1.83 billion euros. At the end of 2019, more than 9,000 employees were working for customers around the globe at the Group’s around 60 production and sales locations.

Novasep in brief

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life science molecules and fine chemicals. Novasep’s unique offering includes process development services, purification systems and turnkey processes, contract manufacturing services and complex active molecules for the pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients industries, as well as for the fermentation and basic chemical industries.

Contact Sartorius
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
[email protected]

Kontakt Novasep
Brice Roquet / Laure Saloin
Communication Project Managers
+33 7 77 94 37 55 / +33 7 77 94 37 52 /

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

[ source link ]

Sartorius takes chromatography process equipment division Novasep Sartorius January #6th


Please enter your comment!
Please enter your name here